Spotify billionaire’s body scan startup has come to America

Preventative health scans costing $500 are now available without insurance coverage, though they may be HSA-eligible.

Neko Health, a body scan startup co-founded by Spotify billionaire Daniel Ek, has launched in the United States, beginning with New York. The company, founded in Sweden, uses advanced technology to screen for issues in blood, skin, and metabolism, having raised nearly $1 billion to date. Neko Health boasts a global waitlist of over 300,000 individuals and aims to address low preventative care utilization in the U.S. The service costs $500 for a one-hour scan, which is not covered by insurance but can be used with Health Savings Accounts. The company plans further U.S. expansion and is working to scale its operations and navigate regulatory approvals. Neko Health's scan has evolved from measuring 15 biomarkers to 55, incorporating computer vision and AI to provide actionable health insights.

Neko Health's arrival in the U.S. signifies a growing trend of tech-driven preventative healthcare solutions aiming to disrupt traditional medical systems. The company's substantial funding and significant waitlist suggest a strong market appetite for accessible, high-tech health screenings, particularly in a country with complex and often costly healthcare access. This move could pressure existing healthcare providers to innovate in preventative services and pricing, while also highlighting the potential for AI and advanced imaging to become standard components of routine health assessments.

The $500 price point, while substantial, positions Neko Health as a premium, yet potentially more accessible, alternative to traditional diagnostic methods, especially for those prioritizing proactive health management. Its expansion will likely be closely watched by both investors and competitors in the health-tech and wellness sectors, as regulatory hurdles and the challenge of integrating with the existing U.S. healthcare infrastructure remain key factors. Success could pave the way for further international health-tech companies to enter the U.S. market.